Malaria Vaccine Development Advances

Posted: November 6th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on Malaria Vaccine Development Advances

GenVec inked a $3.5 million agreement with the Naval Medical Research Center o support malaria vaccine development.

The Gaithersburg, MD-based company will produce supplies of its vaccine for use in clinical trials.  The company retains the right to commercialize the product.  The NMRC will assess the safety and efficacy of the vaccines in a clinical challenge model it developed with Walter Reed Army Institute of Research malaria vaccine programs.  Those programs are now unified as the U.S. Military Vaccine Program.

NMRC and WRAIR tested out GenVec’s candidate in April 2010 in a Phase I trial.  The data from the trial indicated the vaccine is safe, “causing minimal local or systemic reactions and no serious vaccine-related adverse reactions,” according to GenVec’s statement.  And four out of 15 volunteers inoculated with the vaccine showed a complete absence of parasites in the blood.

Comments are closed.